Mounjaro (Tirzepatide) Patent Expiration, LOE Window & CMS Spending

Mounjaro (Tirzepatide) by Eli Lilly: FDA Orange Book core substance LOE 2039-06-14 (last listed 2041-12-30), 0 AB generics, $7.33B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN215866 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-06-14
Last Listed Patent or Exclusivity Date2041-12-30
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.33B
2024 Medicare Part D Spend$6.34B
2024 Medicaid Spend$993.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.